Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07628582 | A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies | PHASE1 | NOT YET_RECRUITING | 48 | — | — | Sep 15, 2026 | Sep 30, 2030 | Jun 5, 2026 | 1 | China |
An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
CAR positive T cells and CAR transgene percentage of in peripheral blood after LVIVO-TaVec122 infusion.
CAR positive T cells and CAR transgene percentage of in bone marrow after LVIVO-TaVec122 infusion.
RP2D established through BF-BOIN design and the dose-limiting toxicity (DLT) occurring following LVIVO-TaVec122 infusion
| Arm | Type | Description |
|---|---|---|
| LVIVO-TaVec122 product | EXPERIMENTAL | Each subject will be given a single-dose LVIVO-TaVec122 product infusion at each dose level. |
| Name | Type | Description |
|---|---|---|
| LVIVO-TaVec122 product | BIOLOGICAL | Prior to infusion of the LVIVO-TaVec122 product, subjects will receive bridging therapy if needed. |
Inclusion Criteria: 1. Subjects voluntary agreement to provide written informed consent. 2. Age ≥ 18 years. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4. At least one evaluable tumor lesion. 5. Relapsed and/or refractory Non-Hodgkin Lymphoma (NHL) , and relapsed and/...